Waystar Holding Corp. (WAY) Stock Price & How to Invest

Waystar Holding (Nasdaq: WAY) sells cloud-based software that healthcare providers use to get paid: financial clearance and eligibility, claims and payer-payment management, denials prevention and recovery, patient payments, and analytics. Its platform sits between roughly a million providers and the payers that reimburse them, processing billions of transactions a year, and the company leans heavily on automation and AI to reduce the manual work in medical billing. Provider-side solutions make up the large majority of revenue and carry high margins, with patient-payment tools rounding out the mix.

The investment picture is one of a scaled, sticky software business that turned the corner on GAAP profitability after its 2024 IPO. Revenue grew about 22% year over year in Q1 2026 (roughly 11% organic, the rest from the Iodine Software acquisition), net revenue retention sits near 111%, and adjusted EBITDA margins run in the low-40s percent. The debate is less about whether the business works and more about valuation: at a mid-30s P/E and a market cap several times trailing revenue, the stock already embeds expectations for sustained growth, successful acquisition integration, and further margin gains.

Concentration and competition are real: Optum (UnitedHealth) can bundle RCM with payer services and undercut on price, while R1 RCM, Availity, and Experian Health all compete for overlapping share. Valuation is the sharpest risk, as a mid-30s P/E leaves little room for a growth or margin stumble, and the stock has traded well below its 52-week high. Growth is partly acquisition-fueled, so integration missteps or slowing organic growth would matter, and the business carries meaningful debt from its buyout and IPO history. Regulatory change in healthcare reimbursement, payer-side pricing pressure, and cybersecurity exposure (a systemic concern for healthcare-payments infrastructure after the 2024 Change Healthcare breach) round out the risk set.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Waystar Holding Corp.'s investor relations page or your broker.

• Revenue (TTM): ~$1.16B
• Market cap: ~$4.6B
• Net income (TTM): ~$126M
• P/E ratio: ~35x
• Adj. EBITDA margin (Q1 2026): ~43%
• 2026 revenue guidance: ~$1.274B to $1.294B

Waystar was trading around $24 in early July 2026, well below its 52-week high, with about 192 million shares outstanding. Q1 2026 revenue rose ~22% year over year to ~$314 million (roughly 11% organic) with net revenue retention near 111%. The mid-30s P/E and a market cap several times trailing revenue reflect expectations for continued double-digit growth and margin expansion rather than a cheap-value setup.

There are three common ways to get WAY exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so WAY sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where WAY fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Waystar is a profitable, fast-growing healthcare-payments software business whose valuation already prices in durable double-digit growth and continued margin expansion.

Whether WAY is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is WAY a buy?, and where the stock could go from here in the WAY stock forecast.

For income investors, whether WAY pays a dividend and how the payout looks is covered in does WAY pay a dividend?